H3 Biomedicine Inc., a start-up focused on cancer treatments based on genetics, is officially unveiling its new 24,000-square-foot office in Cambridge today, another sign of growth at Kendall Square.
H3 Biomedicine currently employs 30 staffers and it looks to add another 40 over the next 12 months, company president and chief executive Markus Warmuth, M.D., said.
The company’s scientific founders include Stuart L. Schreiber, the founding director of chemical biology at the Broad Institute of Harvard and MIT and a professor of chemistry and chemical biology at Harvard University, and Todd R. Golub, founding director of the cancer program at the Broad Institute and a professor of pediatrics at Harvard Medical School.
With the help of up to $200 million in research funding from Eisai Inc., a Japanese pharmaceutical company, H3 Biomedicine is focused on addressing cancer treatments by integrating patient-based cancer genetics with next-generation synthetic chemistry. The belief is that understanding the genetics of patient with cancer can reveal drug targets that can result in treatments tailored to their cancers.
(Eisai has a research-and-development facility in Andover that employs 300 people, the Massachusetts Life Sciences Center noted.)
H3 Biomedicine’s press release included a statement from Susan Windham-Bannister, president and chief executive of the Massachusetts Life Sciences Center.
“Massachusetts provides the ideal environment for a growing drug discovery company as it is home to one of the world’s leading biotechnology clusters, world-class academic and scientific institutions, top teaching hospitals, and the best educated workforce in the United States,” she said.
A Globe story earlier this week noted that plans for 5 million square feet of lab and office space are either underway or under consideration. For its part, the Massachusetts Institute of Technology is preparing to spend $700 million to redevelop eight of its properties in Kendall Square.